IN THIS ISSUE

Jack McCain
They are far less common than many chronic conditions. But by some measures, the financial and health toll from inflammatory bowel disease, rheumatoid arthritis, and psoriasis is comparable to stroke and lower back pain.
Thomas Reinke

Shelley Slade
Vogel, Slade & Goldstein

Hub programs are growing in popularity as a way for pharmaceutical companies to combat the clout of employers, health plans, and PBMs. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.
Legislation & Regulation: Campaign 2016
Richard Mark Kirkner
Adverse selection, other problems may hinder the presumptive Democratic candidate’s proposal to let people buy into Medicare in their 50s.
Value-Based Care
Michael D. Dalzell
CMS’s data-liberation movement is helping to accelerate the transition to value- and risk-based payment systems. For payers and providers, the trick is knowing what to do with the data.
Tomorrow’s Medicine
Thomas Morrow, MD

Thomas Morrow, MD

Studies show Eli Lilly’s Taltz achieves higher remission rates than its main competitor but is also marked by slightly more infections.
Viewpoint
Saskia Siderow
Allison Silvers, MBA
Diane E. Meier, MD
Care targeting pain and symptoms has caught the eye of insurers.
News & Commentary

Marilyn Tavenner
AHIP